Cantor Fitzgerald Reiterates Overweight Rating on Foamix Pharmaceuticals (FOMX) Amid Finacea Foam Settlement
Tweet Send to a Friend
Cantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $15.00 price target on Foamix Pharmaceuticals (NASDAQ: FOMX) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
